What's Dr Lal Pathlabs Ltd share price today. Get Dr Lal Pathlabs Ltd latest news on BSE/NSE stock price live updates, Dr Lal Pathlabs Ltd financial results and overview, Dr Lal Pathlabs Ltd stock ...
The average one-year price target for Dr. Lal PathLabs (NSEI:LALPATHLAB) has been revised to ₹ 1,743.89 / share. This is a decrease of 50.00% from the prior estimate of ₹ 3,487.78 dated December 3, ...
Dr Lal PathLabs is set to see a sharp decline in its quoted share price on Friday, December 19, as the stock turned ex-date for its maiden bonus issue. Today is also the record date for the corporate ...
Hosted on MSN
Dr Lal PathLabs share price in focus: Emkay bullish on BSE 500 company; maintains buy call - 5 reasons why
Dr Lal PathLabs share price in focus: Dr Lal PathLabs on Thursday (April 30) declared its Q4 quarterly results for the financial year 2025-26. Along with the quarterly earnings, the BSE 500 company ...
SN Genelab’s testing capabilities could gain wider reach through Dr Lal's network over time, potentially boosting growth ...
Dr Lal PathLabs Ltd has recently experienced a rally but could not maintain its peak price levels. Experts suggest that the ...
This article first appeared on GuruFocus. Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) is set to release its Q4 2026 earnings on April 30, 2026. The consensus estimate for Q4 2026 revenue is $6.73 billion, ...
This article first appeared on GuruFocus. Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) is set to release its Q1 2027 earnings on Jul 24, 2026. The consensus estimate for Q1 2027 revenue is $7.60 billion, and ...
Dr. Lal PathLabs to acquire 70% stake in SN Genelab, strengthening its genomics expertise and expanding advanced diagnostic ...
Dr Lal PathLabs Ltd will acquire a 70% stake in SN Genelab Private Ltd (SN Gene) from its existing shareholders for up to ₹168 crore, along with a performance-linked earn-out capped at ₹31.5 crore.
PB Fintech flagged potential pressure on general insurance revenue and agent commissions, while saying its life insurance ...
12d
Price Action: Meesho down 4% as Nomura keeps 'reduce' rating; LCC Projects jumps 4% on project win
Among sectors, except metal and pharma, all other sectoral indices were trading lower with Information Technology index shed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results